Jove
Visualize
Contact Us

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Turning Fluids into Data for Precision Oncology: A Multidisciplinary Tumor Board Approach to Malignant Pleural Effusions.

Biomedicines·2026
Same author

Subtype-Dependent Expression Patterns of Core Hippo Pathway Components in Thymic Epithelial Tumors (TETs): An RT-qPCR Study.

Biomedicines·2026
Same author

Autophagy-Related Proteins' Immunohistochemical Expression and Their Potential Role as Biomarkers in Thymic Epithelial Tumors.

Cancers·2026
Same author

Irisin Concentrations in Children and Adolescent Cancer Survivors and Their Relation to Metabolic, Bone, and Reproductive Profile: A Pilot Case-Control Study.

Journal of clinical medicine·2025
Same author

Leveraging artificial intelligence for evidence-based recommendations in uterine fibroid therapy: Addressing the unmet need in German healthcare-A clinical trial.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025
Same author

Hippo Pathway Dysregulation in Thymic Epithelial Tumors (TETs): Associations with Clinicopathological Features and Patients' Prognosis.

International journal of molecular sciences·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Gastrointestinal stromal tumor.

Michael Stamatakos1, Emmanouel Douzinas, Charikleia Stefanaki

  • 14th Department of Surgery, University of Athens, School of Medicine, Attikon General Hospital, Athens, Greece. stamatakosmih@yahoo.gr

World Journal of Surgical Oncology
|August 4, 2009
PubMed
Summary

Gastrointestinal stromal tumors (GISTs) are common GI mesenchymal neoplasms. While surgery is standard, targeted therapies like Imatinib show promise for advanced GIST treatment.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 21, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Area of Science:

  • Gastroenterology
  • Oncology
  • Pathology

Background:

  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the GI tract.
  • GIST is a recently identified tumor entity with rapidly expanding literature.
  • GISTs are a subset of mesenchymal tumors.

Purpose of the Study:

  • To review the current literature on GISTs.
  • To summarize the epidemiology, origin, clinical presentation, and treatment of GISTs.

Main Methods:

  • Extensive literature review of online medical journals and library resources.
  • Literature search up to 2009 using keywords: GIST, Cajal's cells, treatment, Imatinib, KIT.
  • Data abstraction and review of each study.

Main Results:

  • GISTs are suggested to originate from multipotent mesenchymal stem cells.
  • The estimated incidence of GIST is 10-20 per million people annually.
  • Common GIST symptoms include mass or bleeding.

Conclusions:

  • Surgical resection is the primary treatment for localized GIST.
  • Imatinib is approved for advanced GIST treatment.
  • Other agents like everolimus and rapamycin show promising results in clinical trials.